Lesson plan

NMRA-511

NMRA-511, also known as BTRX-323511 or NMRA-323511, is a vasopressin V 1A receptor antagonist which is under development for the treatment of agitation and anxiety disorders. It has been found to reduce threat behaviors in marmosets. The drug was originated by BlackThorn Therapeutics and is under development by Neumora Therapeutics. As of April 2026, it is in phase 1 clinical trials for agitation, whereas no decent development has been reported for anxiety disorders. The chemical structure of NMRA-511 does not yet appear to have been disclosed.

Back to article

Article summary

NMRA-511, also known as BTRX-323511 or NMRA-323511, is a vasopressin V 1A receptor antagonist which is under development for the treatment of agitation and anxiety disorders. It has been found to reduce threat behaviors in marmosets. The drug was originated by BlackThorn Therapeutics and is under development by Neumora Therapeutics. As of April 2026, it is in phase 1 clinical trials for agitation, whereas no decent development has been reported for anxiety disorders. The chemical structure of NMRA-511 does not yet appear to have been disclosed.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.